Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, Leming PD, Spigel DR, Antonia SJ, Horn L, Drake CG, Pardoll DM, Chen L, Sharfman WH, Anders RA, Taube JM, McMiller TL, Xu H, Korman AJ, Jure-Kunkel M, Agrawal S, McDonald D, Kollia GD, Gupta A, Wigginton JM, Sznol M
N Engl J Med. 2012 366 (26): 2443-54

PMID: 22658127 · PMCID: PMC3544539 · DOI:10.1056/NEJMoa1200690

MeSH Terms (16)

Adult Antibodies, Monoclonal Antineoplastic Agents Carcinoma, Non-Small-Cell Lung Carcinoma, Renal Cell Colorectal Neoplasms Dose-Response Relationship, Drug Female Humans Ligands Male Melanoma Neoplasms Nivolumab Programmed Cell Death 1 Receptor Prostatic Neoplasms

Connections (1)

This publication is referenced by other Labnodes entities: